Qiagen meets goals during first quarter of 2015

Qiagen has announced its financial results for the first quarter of 2015, during which it delivered an adjusted net sales total of $298.7 million (189.92 million pounds).

This represented a year-on-year increase of two percent on a constant exchange rate basis, with the company able to deliver on its goals for higher adjusted net sales and earnings at during the period.

Its portfolio of growth drivers now represents about 30 percent of its sales and are expanding at a double-digit pace, with the launch of new products such as the fourth-generation QuantiFERON-TB Gold Plus test and QuantiFERON Monitor test set to further drive momentum.

As such, Qiagen is reaffirming our goals for higher adjusted sales and earnings at constant exchange rates in 2015, with adjusted net sales for the full year expected to rise approximately four percent.

Peer Schatz, chief executive officer of Qiagen, said: "Our results for the first quarter of 2015 show Qiagen continues to deliver a solid performance while moving ahead on our transformation and preparations for a new growth wave."

This comes after the firm recently agreed a strategically important new technology partnership with BGI, the world's largest genomics organisation.